Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients - Report - MDSpire

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients

  • By

  • Guihong Wan

  • Nga Nguyen

  • Charles Lu

  • Sara Khattab

  • Boshen Yan

  • Munachimso Amadife

  • Bonnie W. Leung

  • Wenxin Chen

  • Ahmad Rajeh

  • Kimberly Tang

  • Christopher Thang

  • Genevieve Boland

  • Kerry L. Reynolds

  • Kun-Hsing Yu

  • Alexander Gusev

  • Nicole R. LeBoeuf

  • Shawn G. Kwatra

  • Yevgeniy R. Semenov

  • May 22, 2026

  • 0 min

Share

Clinical Report: Impact of Systemic Glucocorticoid Immunosuppression on Survival Rates

Overview

This study investigates the association between systemic glucocorticoid immunosuppression (gsISP) and overall survival (OS) in patients treated with immune checkpoint inhibitors (ICIs). It highlights the complexities of managing immune-related adverse events (irAEs) and the potential impact of gsISP on treatment outcomes.

Background

Immune checkpoint inhibitors have significantly improved overall survival in various cancers, yet responses can differ widely among patients. Systemic immunosuppression, particularly gsISP, is often employed to manage irAEs, which can complicate the therapeutic landscape. Understanding how gsISP affects ICI outcomes is crucial for optimizing treatment strategies.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • Higher doses of corticosteroids for managing irAEs are associated with poorer survival outcomes in ICI recipients.
  • The meta-analysis by Verheijden et al indicated hazard ratios of 1.66 for 2 mg/kg and 1.21 for 1 mg/kg corticosteroids compared to 0.5 mg/kg.
  • The study utilized a large multi-institutional cohort to examine the effects of gsISP on OS.
  • gsISP was primarily focused on in the analysis, as most patients in the sISP group received glucocorticoids.
  • The impact of timing and duration of corticosteroid therapy on survival remains unclear.

Clinical Implications

Clinicians should be aware of the potential negative impact of higher corticosteroid doses on survival in patients receiving ICIs. The management of irAEs with gsISP requires careful consideration of the timing and dosage to optimize patient outcomes.

Conclusion

The study underscores the need for further research to clarify the relationship between gsISP and ICI efficacy, particularly regarding timing and dosing strategies.

Related Resources & Content

  1. Verheijden et al, 2024 -- Impact of glucocorticoid administration on therapeutic outcomes of immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis
  2. The ASCO Post — Can Diabetes Affect the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Cancer?
  3. The ASCO Post — Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With Immunotherapy
  4. the asco post — Meta-Analysis Reveals How ICIs May Impact Solid Organ Transplant Responses
  5. The ASCO Post — Survival in Male vs Female Patients Receiving Immune Checkpoint Inhibitors
  6. Can Diabetes Affect the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Cancer?
  7. Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With Immunotherapy
  8. Meta-Analysis Reveals How ICIs May Impact Solid Organ Transplant Responses
  9. Open access
  10. Impact of glucocorticoid administration on therapeutic outcomes of immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis - PMC
  11. Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors | Scientific Reports

Original Source(s)

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients

  • by Guihong Wan, Nga Nguyen, Charles Lu, Sara Khattab, Boshen Yan, Munachimso Amadife, Bonnie W. Leung, Wenxin Chen, Ahmad Rajeh, Kimberly Tang, Christopher Thang, Genevieve Boland, Kerry L. Reynolds, Kun-Hsing Yu, Alexander Gusev, Nicole R. LeBoeuf, Shawn G. Kwatra, Yevgeniy R. Semenov

  • May 22, 2026

Related Content

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma